Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Therapeutic Drug Carrier Systems
Fator do impacto: 2.9 FI de cinco anos: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimir: 0743-4863
ISSN On-line: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005268
pages 183-216

Psoriasis Clinical Implications and Treatment: A Review

Ashlesha S. Raut
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga, Mumbai 400 019, India
Rashmi H. Prabhu
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga, Mumbai 400 019, India
Vandana B. Patravale
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga, Mumbai, Maharashtra, India

RESUMO

Psoriasis is a common skin disorder affecting the population worldwide. It is a T-cell mediated autoimmune disorder leading to keratinocyte hyperproliferation. Psoriasis has genetic predisposition that is further aggravated by certain stimulating factors. In spite of significant advances in understanding the pathogenesis of psoriasis, the exact etiology of the disease remains unknown. The clinical manifestations of this disease include various forms that affect different parts of the body. Treatment options vary according to the mode of application or severity of the disease. Earlier treatments have included application of emollients or keratolytic agents to hydrate the skin or shed off the skin. But later treatments have been modified to treat the underlying T-cell proliferation. Hence, topical treatments like coal tar, vitamin D, retinoids, topical calcineurin inhibitors for treating mild psoriasis, systemic treatments including methotrexate, cyclosporine, acitretin, hydroxyurea, as well as light therapy for severe psoriasis have become more prominent. Current treatment modalities are associated with the risk of serious side effects from prolonged treatment. Combinations of these therapies have provided effective and rapid modalities to suppress the disease and reduce the side effects of treatment. In addition, newer carrier systems for conventional drugs are being developed to improve the effectiveness of treatment and reduce the side effects. Development of biologics and gene therapy have revolutionized the treatment of this skin disease. Although an array of therapies to suppress the psoriatic condition exists, none are curative.


Articles with similar content:

Different Advanced Therapeutic Approaches to Treat Vitiligo
Journal of Environmental Pathology, Toxicology and Oncology, Vol.34, 2015, issue 4
Vinay Sharma, Monika Sharma, Chandra Kant Sharma, Bhawna Aggarwal
Ancient and Advanced Approaches for the Treatment of an Inflammatory Autoimmune Disease−Psoriasis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 4
Goutam Rath, Tarun Garg, Amit Kumar Goyal
Gene Therapy for Lung Cancer
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Humberto Lara-Guerra, Jack A. Roth
Options and Opportunities for Clinical Management and Treatment of Psoriasis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 1
Udita Agrawal, Devyani Dube, Madhu Gupta, Suresh P. Vyas
Osteoarthritis: A Critical Review
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.24, 2012, issue 3-4
Eric Y. Chang, Justin Hata, Richard Panush, Kentaro Onishi, Amol Utturkar, Danielle Perret-Karimi